Ignet
v2.0 Sign In

Gene Information

Gene symbol: ERBB2

Gene name: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

HGNC ID: 3430

Synonyms: NEU, HER-2, CD340, HER2

Related Genes

# Gene Symbol Number of hits
1 AKT1 1 hits
2 ALK 1 hits
3 BARD1 1 hits
4 BRAF 1 hits
5 BRCA1 1 hits
6 BRCA2 1 hits
7 CCND1 1 hits
8 CD274 1 hits
9 CDKN1A 1 hits
10 E2F1 1 hits
11 EGFR 1 hits
12 ERBB3 1 hits
13 ESR1 1 hits
14 FGFR1 1 hits
15 FOXA1 1 hits
16 GATA3 1 hits
17 GRN 1 hits
18 HMBS 1 hits
19 IDH2 1 hits
20 JUN 1 hits
21 KIT 1 hits
22 MET 1 hits
23 MKI67 1 hits
24 NEU1 1 hits
25 NOTCH1 1 hits
26 PARP1 1 hits
27 PIK3CA 1 hits
28 PSMD9 1 hits
29 PTEN 1 hits
30 RET 1 hits
31 STK11 1 hits
32 TP53 1 hits

Related Sentences

# PMID Sentence
1 9559296 The method was developed for the c-erbB-2 gene, using the porphobilinogen deaminase (PBGD) gene as an internal standard.
2 11250681 Extensive studies of BRCA1- and BRCA2-associated breast tumours have been carried out in the few years since the identification of these familial breast cancer predisposing genes.
3 11250681 The morphological studies suggest that BRCA1 tumours differ from BRCA2 tumours and from sporadic breast cancers.
4 11250681 Studies to date have investigated issues such as steroid hormone receptor expression, mutation status of tumour suppressor genes TP53 and c-erbB2, and expression profiles of cell cycle proteins p21, p27 and cyclin D1.
5 11250681 BRCA1-associated tumours appear to show an increased frequency of TP53 mutations, frequent p53 protein stabilization and absence of imunoreactivity for steroid hormone receptors.
6 11250681 Further studies of larger number of samples of both BRCA1- and BRCA2-associated tumours are necessary to clarify and confirm these observations.
7 33710534 Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected patients with breast cancer (BC).
8 33710534 Olaparib and talazoparib are PARP inhibitors approved as monotherapies for deleterious/suspected deleterious germline BRCA-mutated, HER2-negative BC.
9 33781053 Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
10 35098723 Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer.
11 35098723 Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer.
12 35098723 Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer.
13 35098723 <b>Aim:</b> We assessed real-world patient demographics and <i>BRCA1/2</i> mutation testing rates among adult women with HER2-negative advanced breast cancer (ABC).
14 35098723 <b>Aim:</b> We assessed real-world patient demographics and <i>BRCA1/2</i> mutation testing rates among adult women with HER2-negative advanced breast cancer (ABC).
15 35098723 <b>Aim:</b> We assessed real-world patient demographics and <i>BRCA1/2</i> mutation testing rates among adult women with HER2-negative advanced breast cancer (ABC).
16 35098723 <i>BRCA1/2</i> mutation testing rates were significantly lower in the European countries, women aged ≥45 years, women without a known family history of breast/ovarian cancer, and women with hormone receptor-positive/HER2-negative ABC versus advanced triple-negative breast cancer.
17 35098723 <i>BRCA1/2</i> mutation testing rates were significantly lower in the European countries, women aged ≥45 years, women without a known family history of breast/ovarian cancer, and women with hormone receptor-positive/HER2-negative ABC versus advanced triple-negative breast cancer.
18 35098723 <i>BRCA1/2</i> mutation testing rates were significantly lower in the European countries, women aged ≥45 years, women without a known family history of breast/ovarian cancer, and women with hormone receptor-positive/HER2-negative ABC versus advanced triple-negative breast cancer.
19 35180531 Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
20 35180531 Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
21 35180531 Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
22 35180531 Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
23 35180531 Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
24 35180531 Therefore, we compared the mutation profiles of early TNBC with those of hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-negative (HER2-) breast cancer using a customized next-generation sequencing capture panel.
25 35180531 Therefore, we compared the mutation profiles of early TNBC with those of hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-negative (HER2-) breast cancer using a customized next-generation sequencing capture panel.
26 35180531 Therefore, we compared the mutation profiles of early TNBC with those of hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-negative (HER2-) breast cancer using a customized next-generation sequencing capture panel.
27 35180531 Therefore, we compared the mutation profiles of early TNBC with those of hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-negative (HER2-) breast cancer using a customized next-generation sequencing capture panel.
28 35180531 Therefore, we compared the mutation profiles of early TNBC with those of hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-negative (HER2-) breast cancer using a customized next-generation sequencing capture panel.
29 35180531 Significant mutations were found in TP53, PIK3CA, AR, BRCA1, PTEN, BRCA2, BRIP2, KIT, MET, AKT1, ALK, BARD1, BRAF, CD274, ERBB2, FGFR1, IDH2, NOTCH1, RET, and STK11 (in descending order of occurrence).
30 35180531 Significant mutations were found in TP53, PIK3CA, AR, BRCA1, PTEN, BRCA2, BRIP2, KIT, MET, AKT1, ALK, BARD1, BRAF, CD274, ERBB2, FGFR1, IDH2, NOTCH1, RET, and STK11 (in descending order of occurrence).
31 35180531 Significant mutations were found in TP53, PIK3CA, AR, BRCA1, PTEN, BRCA2, BRIP2, KIT, MET, AKT1, ALK, BARD1, BRAF, CD274, ERBB2, FGFR1, IDH2, NOTCH1, RET, and STK11 (in descending order of occurrence).
32 35180531 Significant mutations were found in TP53, PIK3CA, AR, BRCA1, PTEN, BRCA2, BRIP2, KIT, MET, AKT1, ALK, BARD1, BRAF, CD274, ERBB2, FGFR1, IDH2, NOTCH1, RET, and STK11 (in descending order of occurrence).
33 35180531 Significant mutations were found in TP53, PIK3CA, AR, BRCA1, PTEN, BRCA2, BRIP2, KIT, MET, AKT1, ALK, BARD1, BRAF, CD274, ERBB2, FGFR1, IDH2, NOTCH1, RET, and STK11 (in descending order of occurrence).
34 35180531 TP53 mutations were identified in the TNBC group more frequently than in the HR+/HER2- group (P = 0.003).
35 35180531 TP53 mutations were identified in the TNBC group more frequently than in the HR+/HER2- group (P = 0.003).
36 35180531 TP53 mutations were identified in the TNBC group more frequently than in the HR+/HER2- group (P = 0.003).
37 35180531 TP53 mutations were identified in the TNBC group more frequently than in the HR+/HER2- group (P = 0.003).
38 35180531 TP53 mutations were identified in the TNBC group more frequently than in the HR+/HER2- group (P = 0.003).
39 35180531 The presence of TP53 mutations was associated with a higher tumor grade (P = 0.008), p53 positivity (P &lt; 0.0001), and a higher Ki-67 index (P = 0.004).
40 35180531 The presence of TP53 mutations was associated with a higher tumor grade (P = 0.008), p53 positivity (P &lt; 0.0001), and a higher Ki-67 index (P = 0.004).
41 35180531 The presence of TP53 mutations was associated with a higher tumor grade (P = 0.008), p53 positivity (P &lt; 0.0001), and a higher Ki-67 index (P = 0.004).
42 35180531 The presence of TP53 mutations was associated with a higher tumor grade (P = 0.008), p53 positivity (P &lt; 0.0001), and a higher Ki-67 index (P = 0.004).
43 35180531 The presence of TP53 mutations was associated with a higher tumor grade (P = 0.008), p53 positivity (P &lt; 0.0001), and a higher Ki-67 index (P = 0.004).
44 35180531 PIK3CA was the most frequently mutated gene in HR+/HER2- breast cancer (8/22, 36.4%), but not in TNBC (1/12, 8.3%).
45 35180531 PIK3CA was the most frequently mutated gene in HR+/HER2- breast cancer (8/22, 36.4%), but not in TNBC (1/12, 8.3%).
46 35180531 PIK3CA was the most frequently mutated gene in HR+/HER2- breast cancer (8/22, 36.4%), but not in TNBC (1/12, 8.3%).
47 35180531 PIK3CA was the most frequently mutated gene in HR+/HER2- breast cancer (8/22, 36.4%), but not in TNBC (1/12, 8.3%).
48 35180531 PIK3CA was the most frequently mutated gene in HR+/HER2- breast cancer (8/22, 36.4%), but not in TNBC (1/12, 8.3%).
49 35180531 The TP53 mutation is associated with higher tumor grade and Ki-67 expression in both groups, and with larger tumor size in TNBC, but not in HR+/HER2- breast cancer.
50 35180531 The TP53 mutation is associated with higher tumor grade and Ki-67 expression in both groups, and with larger tumor size in TNBC, but not in HR+/HER2- breast cancer.
51 35180531 The TP53 mutation is associated with higher tumor grade and Ki-67 expression in both groups, and with larger tumor size in TNBC, but not in HR+/HER2- breast cancer.
52 35180531 The TP53 mutation is associated with higher tumor grade and Ki-67 expression in both groups, and with larger tumor size in TNBC, but not in HR+/HER2- breast cancer.
53 35180531 The TP53 mutation is associated with higher tumor grade and Ki-67 expression in both groups, and with larger tumor size in TNBC, but not in HR+/HER2- breast cancer.
54 37878223 Whereas several topological properties of these GRNs enabled us to identify tumor-related features of ANT, escape velocity centrality (EVC+) identified 24 functionally significant common genes, including well-known genes such as E2F1, FOXA1, JUN, BRCA1, GATA3, ERBB2, and ERBB3 across all six tissues including subtypes and ANT.
55 38100492 Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
56 38247067 [Does Early Olaparib Administration Improve Prognosis in Patients with HER2-Negative Metastatic Breast Cancer and BRCA1 and/or BRCA2 Pathogenic Variants?
57 38279496             Lacking protein functions of Breast cancer susceptibility gene1 (BRCA1) and Breast cancer susceptibility gene2 (BRCA2), by methylation, represents tissue-specific silent epigenetic regions that tolerate genomic instability and may end in different cancers, mainly breast and ovary.
58 38279496             Lacking protein functions of Breast cancer susceptibility gene1 (BRCA1) and Breast cancer susceptibility gene2 (BRCA2), by methylation, represents tissue-specific silent epigenetic regions that tolerate genomic instability and may end in different cancers, mainly breast and ovary.
59 38279496 The extracted DNA was subjected to methylation-specific PCR (MSP) to determine the promoter methylation status of BRCA1 and its correlation with study parameters including protein expression level of ER, PR, Her2/neu, and Ki67 receptors.
60 38279496 The extracted DNA was subjected to methylation-specific PCR (MSP) to determine the promoter methylation status of BRCA1 and its correlation with study parameters including protein expression level of ER, PR, Her2/neu, and Ki67 receptors.
61 38279496 Compared with negative methylation, positive BRCA1 promoter methylation was significantly high among triple negative (ER-, PR-, Her2-) cases with high proliferative index.
62 38279496 Compared with negative methylation, positive BRCA1 promoter methylation was significantly high among triple negative (ER-, PR-, Her2-) cases with high proliferative index.